Your SlideShare is downloading. ×
0
ANTISENSE TECHNOLOGY   Presented By Desh Bandhu Gangwar  M.Tech Biotech (2 year) Concerned Faculty Dr. Gunjan Garg Assista...
INTRODUCTION <ul><li>What is Antisense  Technology ? </li></ul>
 
<ul><li>In this technique Short segments of single stranded DNA  called  oligo   de   oxy   nucleotides   are introduced. ...
<ul><li>Antisense technology prevent the synthesis of specific protein. </li></ul><ul><li>Antisense technologies are a sui...
  Antisense Oligonucleotides   <ul><li>What are Antisense  Oligonucleotides? </li></ul>
<ul><li>The antisense effect of a oligonucleotide sequence was first demonstrated in 1970s by  Zamecnik  and  Stephenson ,...
<ul><li>When these AS-ON combined with target mRNA, a  DNA/RNA   hybrid   form,which degraded by the enzyme  RNase H . </l...
<ul><li>RNase H is a non-specific  endonuclease , catalyzes the cleavage of  RNA  via  hydrolytic mechanism. </li></ul><ul...
Mechanism of antisense activity
Types Of  AS-ON <ul><li>First generation AS-ON </li></ul><ul><li>Second generation AS-ON </li></ul><ul><li>Third generatio...
A successful AS-ON depends on the following characteristics : <ul><li>Unique DNA sequence </li></ul><ul><li>Efficient cell...
First generation AS-ON  <ul><li>First synthesized  by  Eckstein  and  colleagues . </li></ul><ul><li>Phosphorothioate - ol...
Sites of chemical modification
<ul><li>Phosphorothioate linkages in Ons  primarily used to enhance their  nuclease  resistance . </li></ul><ul><li>In thi...
<ul><li>Better stability to nucleases but still degrades. </li></ul><ul><li>Decreased affinity to target mRNA. </li></ul><...
Second generation AS-ON <ul><li>Second generation ONs containing nucleotides with  alkyl modifications   at the 2’ positio...
Characterstics of second generation AS-ON <ul><li>Best stability to nucleases. </li></ul><ul><li>Increased affinity to tar...
Third generation AS-ON <ul><li>Newest and most promising. </li></ul><ul><li>Enhance binding affinity and biostability.  </...
Peptide nucleic acids <ul><li>In PNAs the deoxyribose phosphate backbone is replaced by  polyamide linkages,  which is com...
Locked nucleic acid <ul><li>LNA was synthesized by  Jesper Wengel   in 1998. </li></ul><ul><li>The ribose moiety of LNA nu...
Ribozymes <ul><li>Thomas and coworkers  coined the term ‘ribozymes. </li></ul><ul><li>Ribozymes are RNA molecules that hav...
Mechanism of Ribozymes
Types Of Ribozymes <ul><li>Tetrahymena  group I intron </li></ul><ul><li>RNase P </li></ul><ul><li>Hammer head ribozyme </...
Cycle of RNA cleavage by  hammerhead ribozyme
Ribozymes in  clinical trials <ul><li>ANGIOZYME  -  VEGF-receptor1 </li></ul><ul><li>HERZYME  -  HER-2 </li></ul><ul><li>H...
RNA interference <ul><li>RNA interference (RNAi) is a system within living cells that takes part in controlling  genes act...
Mechanism of RNA interference
Comparision Of different  Antisense stratgies
Applications Of Antisense technologies <ul><li>Story of Flavr Savr… </li></ul>
<ul><li>Antisense therapy  </li></ul><ul><li>ß -thalassemia </li></ul><ul><li>Cytomegalovirus retinitis </li></ul><ul><li>...
<ul><li>Antisense Drug Therapy </li></ul>
REFERENCE <ul><li>Gene cloning and DNA analysis, Fifth edition By T.A Brown Page no. 235 </li></ul><ul><li>Walton, S. P., ...
<ul><li>QUERIES? </li></ul>
<ul><li>THANK YOU </li></ul>
Upcoming SlideShare
Loading in...5
×

Desh bandhu gangwar antisense technology

3,348

Published on

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
3,348
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
171
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide
  • My project is on bioremediation.
  • Transcript of "Desh bandhu gangwar antisense technology"

    1. 1. ANTISENSE TECHNOLOGY Presented By Desh Bandhu Gangwar M.Tech Biotech (2 year) Concerned Faculty Dr. Gunjan Garg Assistant Professor School of Biotechnology
    2. 2. INTRODUCTION <ul><li>What is Antisense Technology ? </li></ul>
    3. 4. <ul><li>In this technique Short segments of single stranded DNA called oligo de oxy nucleotides are introduced. </li></ul><ul><li>These oligonucleotides are complementary to the mRNA, which physically bind to the mRNA . </li></ul>
    4. 5. <ul><li>Antisense technology prevent the synthesis of specific protein. </li></ul><ul><li>Antisense technologies are a suite of techniques that, together form a very powerful weapon for studying gene function and for discovering more specific treatments of disease. </li></ul><ul><li>. </li></ul>
    5. 6. Antisense Oligonucleotides <ul><li>What are Antisense Oligonucleotides? </li></ul>
    6. 7. <ul><li>The antisense effect of a oligonucleotide sequence was first demonstrated in 1970s by Zamecnik and Stephenson , in Rous sarcoma virus. </li></ul><ul><li>AS-ONs usually consist of 15–20 nucleotides , which are complementary to their target mRNA. </li></ul>
    7. 8. <ul><li>When these AS-ON combined with target mRNA, a DNA/RNA hybrid form,which degraded by the enzyme RNase H . </li></ul>RNase H
    8. 9. <ul><li>RNase H is a non-specific endonuclease , catalyzes the cleavage of RNA via hydrolytic mechanism. </li></ul><ul><li> </li></ul><ul><li>RNase H has ribonuclease activity cleaves the 3’-O-P bond of RNA in a DNA/RNA duplex. </li></ul>
    9. 10. Mechanism of antisense activity
    10. 11. Types Of AS-ON <ul><li>First generation AS-ON </li></ul><ul><li>Second generation AS-ON </li></ul><ul><li>Third generation AS-ON </li></ul>
    11. 12. A successful AS-ON depends on the following characteristics : <ul><li>Unique DNA sequence </li></ul><ul><li>Efficient cellular uptake </li></ul><ul><li>Minimal nonspecific binding </li></ul><ul><li>Target specific hybridization </li></ul><ul><li>Non-toxic antisense construct </li></ul><ul><li>Nuclease resistant to protect AS-ON </li></ul>
    12. 13. First generation AS-ON <ul><li>First synthesized by Eckstein and colleagues . </li></ul><ul><li>Phosphorothioate - oligo deoxy nucleotides are the major representatives of first generation DNA analogs that are the best known. </li></ul>
    13. 14. Sites of chemical modification
    14. 15. <ul><li>Phosphorothioate linkages in Ons primarily used to enhance their nuclease resistance . </li></ul><ul><li>In this class of ONs, non bridging oxygen atoms in phopho-diester bond is replaced by sulfur . </li></ul><ul><li>They first used as AS-ONs for the inhibition of HIV. </li></ul>
    15. 16. <ul><li>Better stability to nucleases but still degrades. </li></ul><ul><li>Decreased affinity to target mRNA. </li></ul><ul><li>Enhanced specificity of hybridization. </li></ul><ul><li>Toxic in nature. </li></ul><ul><li>Can activate R Nase H. </li></ul>Characterstics of first generation AS-ON
    16. 17. Second generation AS-ON <ul><li>Second generation ONs containing nucleotides with alkyl modifications at the 2’ position of the ribose. </li></ul><ul><li>2’-O-methyl and 2’-O-methoxy-ethyl RNA are the most important member of this class. </li></ul>
    17. 18. Characterstics of second generation AS-ON <ul><li>Best stability to nucleases. </li></ul><ul><li>Increased affinity to target mRNA. </li></ul><ul><li>Less toxic than first generation AS-ON. </li></ul><ul><li>Can not activate R Nase. </li></ul>
    18. 19. Third generation AS-ON <ul><li>Newest and most promising. </li></ul><ul><li>Enhance binding affinity and biostability. </li></ul><ul><li>Peptide nucleic acids (PNAs) </li></ul><ul><li>Locked nucleic acid (LNA) </li></ul><ul><li>Tricyclo-DNA (tcDNA) </li></ul><ul><li>Cyclohexene nucleic acids (CeNA) </li></ul>
    19. 20. Peptide nucleic acids <ul><li>In PNAs the deoxyribose phosphate backbone is replaced by polyamide linkages, which is composed of repeating N-(2-aminoethyl)-glycine units, linked by peptide bonds </li></ul><ul><li>PNA was first introduced by Nielsen and coworkers in 1991. </li></ul><ul><li>They are electrostatically neutral molecules </li></ul>
    20. 21. Locked nucleic acid <ul><li>LNA was synthesized by Jesper Wengel in 1998. </li></ul><ul><li>The ribose moiety of LNA nucleotide is modified with an extra bridge connecting the 2' oxygen and 4' carbon </li></ul>
    21. 22. Ribozymes <ul><li>Thomas and coworkers coined the term ‘ribozymes. </li></ul><ul><li>Ribozymes are RNA molecules that have catalytic activity. </li></ul><ul><li>Ribozyme Bind to the target RNA moiety and inactivate it by cleaving the phosphodiester backbone at a specific cutting site. </li></ul>
    22. 23. Mechanism of Ribozymes
    23. 24. Types Of Ribozymes <ul><li>Tetrahymena group I intron </li></ul><ul><li>RNase P </li></ul><ul><li>Hammer head ribozyme </li></ul><ul><li>Hairpin ribozyme </li></ul><ul><li>Hepatitis delta virus ribozyme </li></ul>
    24. 25. Cycle of RNA cleavage by hammerhead ribozyme
    25. 26. Ribozymes in clinical trials <ul><li>ANGIOZYME - VEGF-receptor1 </li></ul><ul><li>HERZYME - HER-2 </li></ul><ul><li>HEPTAZYM </li></ul>
    26. 27. RNA interference <ul><li>RNA interference (RNAi) is a system within living cells that takes part in controlling genes activity. </li></ul><ul><li>Two types of small RNA molecules – (miRNA) and (siRNA) are central to RNA interference. </li></ul><ul><li>Mello and Fire named the process RNAi, were awarded the Nobel Prize. </li></ul>
    27. 28. Mechanism of RNA interference
    28. 29. Comparision Of different Antisense stratgies
    29. 30. Applications Of Antisense technologies <ul><li>Story of Flavr Savr… </li></ul>
    30. 31. <ul><li>Antisense therapy </li></ul><ul><li>ß -thalassemia </li></ul><ul><li>Cytomegalovirus retinitis </li></ul><ul><li>Hemorrhagic fever viruses </li></ul><ul><li>Duchenne muscular dystrophy </li></ul><ul><li>Cancer </li></ul><ul><li>HIV/AIDS </li></ul><ul><li>High cholesterol </li></ul>
    31. 32. <ul><li>Antisense Drug Therapy </li></ul>
    32. 33. REFERENCE <ul><li>Gene cloning and DNA analysis, Fifth edition By T.A Brown Page no. 235 </li></ul><ul><li>Walton, S. P., Roth, C. M., Yarmush, M. L. “Antisense Technology.”The Biomedical Engineering Handbook: Second Edition. </li></ul><ul><li>Indian journal of chemistry vol. 48 B December 2009, pp. 1721-1726 </li></ul><ul><li>Indian journal of biotechnology vol 4,JUL 2005,pp. 316 -322 </li></ul><ul><li>Eur. J. Biochem. 270,1628–1644 </li></ul><ul><li>Clinical and Experimental Pharmacology and Physiology (2006) 33, 533–540 </li></ul>
    33. 34. <ul><li>QUERIES? </li></ul>
    34. 35. <ul><li>THANK YOU </li></ul>
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×